\n \n 29 April 2022\n \n
\n\n \n\n \n \n \n \n \n\n\n \n 21 December 2021\n \n
\n\n \n\n \n \n \nJenner researchers have published a pre-print on how new adenovirus-based vaccines could be produced at large-scale within 100 days of identification of a new virus or variant. They also report an improved manufacturing method which could enable production of 1 billion doses per month. The paper is being submitted to BioRxiv and a peer-reviewed journal, and is temporarily available here:
\n \n\n\n \n 15 December 2021\n \n
\n\n \n\n \n \n \nThe Poonawalla Vaccines Research Building is to be established at Oxford University's Old Road Campus following a \u00a350m funding commitment from Serum Life Sciences, a subsidiary of Serum Institute of India. The building will be a new home for the Jenner Institute. The donation will be the University\u2019s largest ever gift for vaccines research.
\n \n\n\n \n 10 December 2021\n \n
\n\n \n\n \n \n \nIn this open call TRANSVAC2 offers free advanced courses on Adjuvants and Vaccine Formulations, Statistics of vaccine evaluation, and Regulatory aspects of vaccine development. Apply until December 15th at www.transvac.org.
\n \n\n\n \n 7 December 2021\n \n
\n\n \n\n \n \n \nFeaturing notable speakers from business, science or politics since 1972, Prof. Gilbert delivered the 44th Richard Dimbleby Lecture, held this year at Oxford's Blavatnik School of Government. Dame Sarah Gilbert is the Sa\u00efd Professor of Vaccinology, at the Jenner Institute & Nuffield Department of Clinical Medicine.\r\n\r\nThe lecture is available (in the UK) via the BBC iPlayer.
\n \n\n\n \n 1 December 2021\n \n
\n\n \n\n \n \n \nThe Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) is pleased to announce the completion of recruitment of volunteers for the Phase I HIV-CORE 006 HIV vaccine clinical trial at four sites in Kenya, Uganda and Zambia. Enrolment of the final participants took place today at the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya, on World AIDS Day.
\n \n\n\n \n 30 November 2021\n \n
\n\n \n\n \n \n \nThe 2021 Royal Society Africa Prize Seminar will be given by Professor George Warimwe, Jenner Investigator. More than 70% of these infectious diseases are zoonotic, with some causing illness and death in humans as well as the animal host. Professor Warimwe will discuss his \u2018one health' approach to developing a single Rift Valley Fever vaccine suitable for humans and livestock. \r\n\r\nThe lecture will take place online 2 December at 6.30pm GMT.
\n \n\n\n \n 29 November 2021\n \n
\n\n \n\n \n \n \nThe team at the University of Oxford\u2019s Jenner Institute has been celebrated for their global pandemic work by The Oxford Trust\u2019s Covid Innovation Heroes Award\u00ad 2021.
\n \n\n\n \n 16 November 2021\n \n
\n\n \n\n \n \n \nUniversity researchers reveal invention of simple manufacturing method which has enabled rapid scale up of vaccine manufacturing in 15 countries around the world, reaching people across seven continents. The approach provides a template for faster and more equitable supply of other vaccines.
\n \n\n\n \n 16 November 2021\n \n
\n\n \n\n \n \n \nThe University of Oxford is to benefit from $2 million (\u00a31.49 million) in funding from the Chan Zuckerberg Initiative (CZI) to investigate how our ancestry and diversity influence the way that vaccines work in our cells.\r\n\r\nThe Oxford team includes a number of investigators across several departments including the Jenner Institute.\r\n\r\nFind out more: (https://www.ox.ac.uk/news/2021-11-16-2m-fund-awarded-oxford-s-single-cell-ancestry-vaccine-research)
\n \n\n\n \n 11 November 2021\n \n
\n\n \n\n \n \n \nThe University of Oxford have begun recruiting for a Phase I trial to test an Ebola vaccine in human volunteers \u2013 with the first vaccinations having already taken place.
\n \n\n\n \n 4 October 2021\n \n
\n\n \n\n \n \n \nThe Oxfordshire Local Enterprise Partnership (OxLEP) has secured funding to support the University of Oxford\u2019s Clinical BioManufacturing Facility (CBF) \u2013 a UK leader in the production of vaccines for early phase clinical trials, including the Oxford-AstraZeneca vaccine.
\n \n\n\n \n 3 September 2021\n \n
\n\n \n\n \n \n \nResearch from Jenner Institute and Ludwig Institute for Cancer Research has shown the technology behind the Oxford-AstraZeneca COVID-19 vaccine has potential in treating cancer. When tested in mice, the cancer vaccine increased levels of anti-tumour T cells infiltrating tumours and improved efficacy of cancer immunotherapy. Compared to immunotherapy alone, the combination with the vaccine showed a greater reduction in tumour size and improved survival of the mice.
\n \n\n\n \n 23 August 2021\n \n
\n\n \n\n \n \n \nThe Royal Society Africa Prize 2021 is awarded to Professor George Warimwe, Jenner Investigator, for his work on zoonoses vaccine development, capacity building in Africa, and his innovative research proposal. Professor Warimwe will be awarded a medal and a grant of \u00a315,000 towards his research project at a symposium to be held at a future date.
\n \n\n\n \n 20 August 2021\n \n
\n\n \n\n \n \n \nThe Oxford-run VALIDATE Network, co-directed by Jenner Investigator Prof Helen McShane, has received $1.5 million in funding for its tuberculosis vaccine work from the Bill & Melinda Gates Foundation. An effective vaccine for TB is one of the primary goals of the VALIDATE Network which aims to accelerate vaccine development for complex intracellular pathogens that are often neglected.
\n \n\n\n \n 6 August 2021\n \n
\n\n \n\n \n \n \nAs the University was planning the first clinical trials for the COVID-19 vaccine, some began to wonder how to supply the vaccine to the world - if it worked. Although Oxford had the capacity to develop a COVID-19 vaccine, and clinical trials might take only a few months, manufacturing \u2018at pandemic scale\u2019 would take much longer. A group of University scientists had, however, worked on the problem for some time.
\n \n\n\n \n 4 August 2021\n \n
\n\n \n\n \n \n \nThe course provides teaching in human and veterinary vaccinology by an exceptional faculty of academic and industrial speakers, with an emphasis on strengthening vaccine development and manufacturing autonomy in Africa. The course alternates between East and West Africa. In 2021, participation is for attendees working or studying in East Africa. Applications close 31 August.
\n \n\n\n \n 3 August 2021\n \n
\n\n \n\n \n \n \nProfessor Tomas Hanke, Professor of Vaccine Immunology at the Jenner Institute, and lead researcher on the trial, said: \u2018This highly rational, bioinformatics-assisted, vaccine design addresses the enormous variability of HIV-1 - one of the greatest challenges to the development of an effective vaccine against HIV/AIDS.\u2019
\n \n\n\n \n 29 July 2021\n \n
\n\n \n\n \n \n \nThe University of Oxford\u2019s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca\u2019s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.
\n \n\n\n \n 16 July 2021\n \n
\n\n \n\n \n \n \nAdenovirus vaccine vectors, such as the ChAdOx1 nCov-19 construct which has risen to prominence as a major vaccine for COVID-19, may generate robust long-term immune system responses, according to scientists from the Universities of Oxford and the Cantonal Hospital St.Gallen, Switzerland.
\n \n\n